To include your compound in the COVID-19 Resource Center, submit it here.

Bradycor bradykinin antagonist: Began a Phase II trial in 160 patients. End points will be improved intracranial pressure and outcome on the Glasgow Coma Score,

Cortech Inc. (CRTQ), Denver
Product: Bradycor

Read the full 65 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE